SCHEMBL4593904

SCHEMBL4593904

O=C(O)c1ccc(Nc2cccc3ccccc23)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.70
CDC25B P30305 4/20 0.68
ATM Q13315 2/20 0.68
TSHR P16473 2/20 0.68
CYP3A4 P08684 2/20 0.68
HSD17B10 Q99714 2/20 0.68
ALDH1A1 P00352 1/20 0.68
TP53 P04637 1/20 0.68
HPGD P15428 1/20 0.68
ALOX15 P16050 1/20 0.68
RAB9A P51151 4/20 0.55
KDM4E B2RXH2 3/20 0.55
MAPT P10636 3/20 0.55
GAA P10253 2/20 0.55
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
NPC1 O15118 2/20 0.55
EGFR P00533 1/20 0.55
KDR P35968 1/20 0.55
CYP1A2 P05177 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29050935 0.85 CDC25B (0.70) POLBCDC25BATMTSHRCYP3A4
SCHEMBL651572 0.84 HSD17B10 (0.87) CDC25BATMTSHRCYP3A4HSD17B10
SCHEMBL29619354 0.84 HSD17B10 (0.87) CDC25BATMTSHRCYP3A4HSD17B10
SCHEMBL4594929 0.83 RCE1 (0.56) POLBCDC25BATMTSHRCYP3A4
SCHEMBL4594357 0.83 RAB9A (0.63) POLBCDC25BATMTSHRCYP3A4
SCHEMBL29609502 0.82 ALDH1A1 (0.92) POLBCDC25BATMTSHRCYP3A4
SCHEMBL4797443 0.82 ALDH1A1 (0.92) POLBCDC25BATMTSHRCYP3A4
SCHEMBL29350230 0.82 ALDH1A1 (1.00) POLBCDC25BATMTSHRCYP3A4
SCHEMBL19796 0.82 ALDH1A1 (1.00) POLBCDC25BATMTSHRCYP3A4
SCHEMBL14542869 0.81 POLB (0.52) POLBCDC25BATMTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101291665-A Naphthyl derivatives as inhibitors of beta-amyloid aggregation SIGMA TAU IND FARMACEUTI (IT) 2008-10-22 CN claimed
US-20080255232-A1 Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-10-16 US claimed
EP-1937243-A2 NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) 2008-07-02 EP claimed
WO-2007045593-A2 NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2007-04-26 WO claimed
CN-116730980-A Compound and stereoisomer thereof, or pharmaceutically acceptable salt and application thereof 合肥工业大学智能制造技术研究院 2023-09-12 CN disclosed
US-7939546-B2 Quinoline derivatives for modulating DNA methylation SUPERGEN, INC. (US) 2011-05-10 US disclosed
US-20090285772-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION SUPERGEN, INC. (US) 2009-11-19 US disclosed
CN-101291665-A Naphthyl derivatives as inhibitors of beta-amyloid aggregation SIGMA TAU IND FARMACEUTI (IT) 2008-10-22 CN disclosed
US-20080255232-A1 Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-10-16 US disclosed
US-20080255232-A1 Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-10-16 US disclosed
US-20080255232-A1 Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-10-16 US disclosed
EP-1937243-A2 NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) 2008-07-02 EP disclosed
WO-2007045593-A2 NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2007-04-26 WO disclosed
WO-2007045593-A2 NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285772-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION DNMT1, DNMT3A, DNMT3L POLB 187/4885CDC25B 466/4885ATM 572/4885
US-20080255232-A1 Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation APP, BACE1, SNCA POLB 1245/4885CDC25B 2914/4885ATM 3630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.